Latest News

PipelineReview

Senhwa Biosciences Announces Dose Escalation Initiation of the Phase I Trial of Pidnarulex as a Treatment for Advanced Hematological Malignancies

Aug

26

2021

OncLive

Silmitasertib Gets Fast Track Status for Recurrent Sonic Hedgehog–Driven Medulloblastoma

Aug

26

2021

Market Watch

Senhwa’s Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma

Aug

18

2021

Yahoo Finance

Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19

Aug

16

2021

PR Newswire

Senhwa Signs Agreement with Taiwan’s CDE for COVID-19 Program Guiding Development of Silmitasertib

Aug

14

2021

Focus Taiwan

CORONAVIRUS/Taiwan COVID-19 drug gets positive review, clinical trials to advance

Mar

15

2021

PR Newswire

Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference

Sep

27

2021

BEING WELL

Is Silmitasertib the Covid-19 Treatment Breakthrough We’ve Been Waiting for?

Sep

14

2020